{"id":"augment-with-aripiprazole","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Akathisia"},{"rate":"10-15","effect":"Headache"},{"rate":"8-12","effect":"Nausea"},{"rate":"8-10","effect":"Insomnia"},{"rate":"5-10","effect":"Tremor"},{"rate":"5-8","effect":"Weight gain"},{"rate":"5-8","effect":"Somnolence"}]},"_chembl":{"chemblId":"CHEMBL2219425","moleculeType":"Small molecule","molecularWeight":"660.73"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Aripiprazole acts as a partial agonist rather than a full antagonist, allowing it to stabilize dopamine signaling by increasing activity when dopamine is low and decreasing it when dopamine is high. This mechanism is thought to reduce both positive symptoms (hallucinations, delusions) and negative symptoms (apathy, withdrawal) of psychotic disorders while potentially causing fewer extrapyramidal side effects than typical antipsychotics. The drug also has activity at 5-HT1A receptors, contributing to its anxiolytic and mood-stabilizing properties.","oneSentence":"Aripiprazole is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors that modulates dopaminergic and serotonergic neurotransmission in the brain.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:29:35.037Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Augmentation therapy for major depressive disorder (Phase 2 indication)"},{"name":"Schizophrenia and schizoaffective disorder (established indication for aripiprazole)"}]},"trialDetails":[{"nctId":"NCT06433635","phase":"PHASE4","title":"Sequential Multiple Assignment Randomized Trial for Bipolar Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-10-01","conditions":"Bipolar I Disorder, Depression","enrollment":2726},{"nctId":"NCT06236451","phase":"PHASE4","title":"Atypical Antipsychotic-induced Mitochondrial Dysfunction in Patients With Schizophrenia","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2024-04-05","conditions":"Schizophrenia","enrollment":60},{"nctId":"NCT06581302","phase":"NA","title":"Magnetic Seizure Therapy for Psychotic Disorders","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2024-09-01","conditions":"Psychotic Disorders","enrollment":50},{"nctId":"NCT04539951","phase":"PHASE2","title":"Pragmatic Trial of Obsessive-compulsive Disorder","status":"RECRUITING","sponsor":"Shanghai Mental Health Center","startDate":"2020-09-22","conditions":"Obsessive-Compulsive Disorder","enrollment":1600},{"nctId":"NCT02431702","phase":"PHASE3","title":"A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-07-08","conditions":"Schizophrenia, Psychotic Disorders","enrollment":337},{"nctId":"NCT04789915","phase":"PHASE1","title":"Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis","status":"RECRUITING","sponsor":"Bjorn H. Ebdrup","startDate":"2021-05-26","conditions":"Psychosis, Negative Symptoms With Primary Psychotic Disorder","enrollment":46},{"nctId":"NCT05531591","phase":"PHASE4","title":"RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT)","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"2019-08-01","conditions":"Depression, Dementia, Mild Cognitive Impairment","enrollment":87},{"nctId":"NCT02960763","phase":"PHASE4","title":"Optimizing Outcomes of Treatment-Resistant Depression in Older Adults","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2017-02-24","conditions":"Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression","enrollment":742},{"nctId":"NCT02822092","phase":"","title":"Striatal Connectivity and Clinical Outcome in Psychosis","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2016-07","conditions":"Psychotic Disorders","enrollment":196},{"nctId":"NCT05889234","phase":"","title":"Multimodal Magnetic Resonance Imaging-based Study of Electroconvulsive Efficacy Prediction in Adolescents With Depression: a Multicenter Prospective Cohort Study","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2023-11-06","conditions":"Major Depressive Disorder, Magnetic Resonance Imaging, Electroconvulsive Therapy","enrollment":180},{"nctId":"NCT00468130","phase":"NA","title":"Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children","status":"COMPLETED","sponsor":"University of Medicine and Dentistry of New Jersey","startDate":"2006-05","conditions":"Autism","enrollment":13},{"nctId":"NCT01111565","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-10-04","conditions":"Major Depressive Disorder (MDD)","enrollment":137},{"nctId":"NCT01111552","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-07-29","conditions":"Major Depressive Disorder (MDD)","enrollment":237},{"nctId":"NCT01111539","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-07-13","conditions":"Major Depressive Disorder (MDD)","enrollment":211},{"nctId":"NCT01418339","phase":"PHASE3","title":"Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2011-07-27","conditions":"Tourette's Disorder","enrollment":135},{"nctId":"NCT04963257","phase":"PHASE4","title":"Sertraline Combined With Fluvoxamine in the Treatment of Refractory Obsessive-compulsive Disorder","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-01-01","conditions":"OCD","enrollment":400},{"nctId":"NCT02146547","phase":"PHASE4","title":"European Long-acting Antipsychotics in Schizophrenia Trial","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2015-02","conditions":"Schizophrenia","enrollment":536},{"nctId":"NCT00712270","phase":"PHASE4","title":"Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia","status":"TERMINATED","sponsor":"Kettering Health Network","startDate":"2005-04","conditions":"Schizophrenia","enrollment":21},{"nctId":"NCT02630888","phase":"PHASE2","title":"Efficacy of Memantine add-on in the Treatment of Bipolar Disorder (Type I) Nonresponders or Partial Responders Patients","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2014-08","conditions":"Bipolar Disorder","enrollment":44},{"nctId":"NCT01338298","phase":"NA","title":"Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2011-01","conditions":"Hyperprolactinemia","enrollment":60},{"nctId":"NCT00953745","phase":"NA","title":"Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2009-05","conditions":"Major Depressive Disorder","enrollment":43},{"nctId":"NCT00509067","phase":"PHASE2","title":"Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2007-11","conditions":"Schizophrenia","enrollment":43},{"nctId":"NCT00667745","phase":"PHASE4","title":"Effectiveness of Lithium Plus Optimized Medication in Treating People With Bipolar Disorder","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2008-04","conditions":"Bipolar Disorder","enrollment":283},{"nctId":"NCT01942161","phase":"PHASE2, PHASE3","title":"A Short Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2010-08","conditions":"Schizophrenia","enrollment":106},{"nctId":"NCT00806234","phase":"PHASE4","title":"Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2009-01","conditions":"Psychotic Disorders","enrollment":127},{"nctId":"NCT01085383","phase":"PHASE4","title":"Aripiprazole and Prolactin Study","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2010-04","conditions":"Hyperprolactinemia","enrollment":15},{"nctId":"NCT00221962","phase":"PHASE4","title":"Study of Aripiprazole (Abilify) in Children With ADHD (Attention Deficit Hyperactivity Disorder)","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2005-04","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":23},{"nctId":"NCT00466310","phase":"PHASE1","title":"Metabolic Signatures and Biomarkers in Schizophrenia","status":"COMPLETED","sponsor":"Duke University","startDate":"2007-02","conditions":"Schizophrenia","enrollment":71},{"nctId":"NCT00198055","phase":"PHASE2","title":"A Study of Aripiprazole in Children and Adolescents With Aspergers and Pervasive Developmental Disorder.","status":"COMPLETED","sponsor":"Indiana University School of Medicine","startDate":"2005-01","conditions":"Asperger's Disorder, Pervasive Developmental Disorder","enrollment":25},{"nctId":"NCT01323205","phase":"PHASE2","title":"Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-05","conditions":"Schizophrenia","enrollment":100},{"nctId":"NCT00216476","phase":"PHASE3","title":"A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2004-10","conditions":"Schizophrenia, Psychotic Disorders","enrollment":753},{"nctId":"NCT02069977","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of Aripiprazole","status":"UNKNOWN","sponsor":"Yoo-Sook Joung","startDate":"2014-02","conditions":"Autism","enrollment":79},{"nctId":"NCT01495156","phase":"PHASE4","title":"Study of the Efficacy of Adjunctive Lithium Treatment for the Treatment of Psychotic Mania","status":"WITHDRAWN","sponsor":"Northwell Health","startDate":"2011-09","conditions":"Bipolar I Disorder","enrollment":""},{"nctId":"NCT00665366","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2008-06","conditions":"Bipolar Disorder Mania","enrollment":493},{"nctId":"NCT00365859","phase":"PHASE3","title":"Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2006-09","conditions":"Autistic Disorder, Behavioral Symptoms","enrollment":330},{"nctId":"NCT00102063","phase":"PHASE3","title":"Aripiprazole in Adolescents With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2004-07","conditions":"Schizophrenia","enrollment":302},{"nctId":"NCT01488266","phase":"NA","title":"Aripiprazole Augmentation Versus Switching to Different Class of Antidepressants in Major Depressive Disorder","status":"UNKNOWN","sponsor":"Korea University","startDate":"2011-11","conditions":"Major Depressive Disorder","enrollment":90},{"nctId":"NCT00211302","phase":"NA","title":"Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (BMS)","status":"TERMINATED","sponsor":"Louisiana State University Health Sciences Center Shreveport","startDate":"2003-08","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":8},{"nctId":"NCT00211380","phase":"NA","title":"Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (SFBRI)","status":"TERMINATED","sponsor":"Louisiana State University Health Sciences Center Shreveport","startDate":"2003-08","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":451,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Augment with Aripiprazole","genericName":"Augment with Aripiprazole","companyName":"Shanghai Mental Health Center","companyId":"shanghai-mental-health-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aripiprazole is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors that modulates dopaminergic and serotonergic neurotransmission in the brain. Used for Augmentation therapy for major depressive disorder (Phase 2 indication), Schizophrenia and schizoaffective disorder (established indication for aripiprazole).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}